- HOME /
- 2023年 3月
The 2023 revision of drug prices in Japan has been announced,
続きを読む
Sanofi’s LIBTAYO, Cemiplimab IV, was approved in December 2022
続きを読む
CSL Behring’s BERINERT SC was approved for prevention of acute hereditary angioedema attacks, HAE, in September 2022.
続きを読む